/**/ RNS Number : 1881D Imaging Biometrics Limited 14 October 2025   14 October 2025   Imaging Biometrics Limited (“IBAI” or the “Company“)   Purchase of Kirkstall Limited and CLN with Truetide plc   Imaging Biometrics Limited (LSE: IBAI), is pleased to announce the purchase of 86.11% of the issued share capital of Kirkstall Limited

/**/ RNS Number : 0412C Imaging Biometrics Limited 03 October 2025     Imaging Biometrics Limited (“IB” or the “Company”)   Vivan Therapeutics and Imaging Biometrics Announce Strategic Partnership to Advance Gallium Maltolate for New Cancer Indications   The collaboration leverages innovative in vivo whole animal high-throughput drug screening platform to explore new anti-cancer uses

/**/ RNS Number : 5731Z Imaging Biometrics Limited 16 September 2025   Imaging Biometrics Limited (the “Company”)   Imaging Biometrics Enters Agreement with MedImageMetric to Commercialize QSM Technology   September 16, 2025 – Imaging Biometrics, LLC (IB), a leading provider of advanced MRI analytics, is pleased to announce an agreement with MedImageMetric, LLC (MIM) to

/**/ RNS Number : 1953V Imaging Biometrics Limited 13 August 2025   13 August 2025 Imaging Biometrics, Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2025   The Board of Imaging Biometrics, Ltd is pleased to announce the Company’s half yearly report for the period ended 30 June

/**/ RNS Number : 4317U Imaging Biometrics Limited 07 August 2025     Imaging Biometrics Limited (“IB” or the “Company”)   Grant of Share Options   The Board of Directors of IB approved, at the February board meeting of the Company, the issuance of incentive share option awards (“Options”) to key personnel as part of

/**/ RNS Number : 8287R Imaging Biometrics Limited 21 July 2025   Imaging Biometrics Limited (“IB” or the “Company”)     Imaging Biometrics Announces Soft Close to Phase 1 Trial of Oral Gallium Maltolate for Relapsed or Refractory Glioblastoma   Elm Grove, WI – July 21, 2025 – Imaging Biometrics, LLC, a leader in quantitative

/**/ RNS Number : 4320Q Imaging Biometrics Limited 09 July 2025   Imaging Biometrics Limited (“IB” or the “Company”)   PDMR dealing   Imaging Biometrics Limited, a leader in quantitative imaging solutions and novel therapies for CNS malignancies, announces that it has been notified of the following transactions in ordinary shares in the Company undertaken

/**/ RNS Number : 5919M Imaging Biometrics Limited 12 June 2025   Imaging Biometrics, Ltd (“IB” or the “Company”)   Imaging Biometrics Provides Update on Breakthrough Therapy Designation Application   Imaging Biometrics, Ltd, a leader in quantitative imaging solutions and novel therapies for CNS malignancies, today announces that following recent dialogue with the U.S. Food

/**/ RNS Number : 1221K Imaging Biometrics Limited 27 May 2025     Imaging Biometrics Limited (“IB” or the “Company”)   Change of Name   The Company is pleased to announce that, further to the announcement made on 29 April 2025, the Company has now formally changed its name from IQ-AI Ltd to Imaging Biometrics Ltd at

/**/ RNS Number : 8413J IQ-AI Limited 22 May 2025     IQ-AI Limited (“IQ-AI” or the “Company”)   Result of AGM   IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed.   For information, the proxy votes received prior to the meeting were